Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Establishment and Genetic Landscape of Precancer Cell Model Systems from the Head and Neck Mucosal Lining.

de Boer DV, Brink A, Buijze M, Stigter-van Walsum M, Hunter KD, Ylstra B, Bloemena E, Leemans CR, Brakenhoff RH.

Mol Cancer Res. 2018 Sep 17. doi: 10.1158/1541-7786.MCR-18-0445. [Epub ahead of print]

PMID:
30224542
2.

Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck.

de Boer DV, Martens-de Kemp SR, Buijze M, Stigter-van Walsum M, Bloemena E, Dietrich R, Leemans CR, van Beusechem VW, Braakhuis BJM, Brakenhoff RH.

Oncotarget. 2017 May 16;8(58):97928-97940. doi: 10.18632/oncotarget.17880. eCollection 2017 Nov 17.

3.

System for CT-guided needle placement in the thorax and abdomen: A design for clinical acceptability, applicability and usability.

Arnolli MM, Buijze M, Franken M, de Jong KP, Brouwer DM, Broeders IAMJ.

Int J Med Robot. 2018 Feb;14(1). doi: 10.1002/rcs.1877. Epub 2017 Dec 5.

PMID:
29205787
4.

Noninvasive molecular screening for oral precancer in Fanconi anemia patients.

Smetsers SE, Velleuer E, Dietrich R, Wu T, Brink A, Buijze M, Deeg DJ, Soulier J, Leemans CR, Braakhuis BJ, Brakenhoff RH.

Cancer Prev Res (Phila). 2015 Nov;8(11):1102-11. doi: 10.1158/1940-6207.CAPR-15-0220. Epub 2015 Aug 14.

5.

Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC.

Nagel R, Stigter-van Walsum M, Buijze M, van den Berg J, van der Meulen IH, Hodzic J, Piersma SR, Pham TV, Jiménez CR, van Beusechem VW, Brakenhoff RH.

Mol Cancer Ther. 2015 Jun;14(6):1434-44. doi: 10.1158/1535-7163.MCT-14-0846. Epub 2015 Mar 25.

6.

A damper driven robotic end-point manipulator for functional rehabilitation exercises after stroke.

Westerveld AJ, Aalderink BJ, Hagedoorn W, Buijze M, Schouten AC, Kooij Hv.

IEEE Trans Biomed Eng. 2014 Oct;61(10):2646-54. doi: 10.1109/TBME.2014.2325532. Epub 2014 May 19.

PMID:
24860023
7.

TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients.

Braakhuis BJ, Rietbergen MM, Buijze M, Snijders PJ, Bloemena E, Brakenhoff RH, Leemans CR.

Oral Dis. 2014 Sep;20(6):602-8. doi: 10.1111/odi.12178. Epub 2013 Sep 23.

PMID:
24112103
8.

Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines.

Nagel R, Martens-de Kemp SR, Buijze M, Jacobs G, Braakhuis BJ, Brakenhoff RH.

Oral Oncol. 2013 Jun;49(6):560-6. doi: 10.1016/j.oraloncology.2013.03.446. Epub 2013 Apr 8.

9.

Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.

Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, Buijze M, Bloemena E, Snijders PJ, Leemans CR, Braakhuis BJ.

Clin Cancer Res. 2011 Jun 1;17(11):3733-41. doi: 10.1158/1078-0432.CCR-11-0183. Epub 2011 Apr 5.

10.

Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma.

Graveland AP, Golusinski PJ, Buijze M, Douma R, Sons N, Kuik DJ, Bloemena E, Leemans CR, Brakenhoff RH, Braakhuis BJ.

Int J Cancer. 2011 Apr 15;128(8):1852-9. doi: 10.1002/ijc.25523.

11.

Differential Proteomics Identifies Protein Biomarkers That Predict Local Relapse of Head and Neck Squamous Cell Carcinomas.

Schaaij-Visser TB, Graveland AP, Gauci S, Braakhuis BJ, Buijze M, Heck AJ, Kuik DJ, Bloemena E, Leemans CR, Slijper M, Brakenhoff RH.

Clin Cancer Res. 2009 Dec 15;15(24):7666-7675.

Supplemental Content

Loading ...
Support Center